Strong increase in sales in 2021 and improved earnings outlook

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 20 January 2022

The Galenica Group can look back on an extremely successful financial year 2021: consolidated net sales increased by 10.2% to CHF 3,834.7 million. As a result, Galenica significantly exceeded the sales guidance published in August 2021.

Business overall saw a very dynamic development – especially in the last few months of 2021. On the one hand, extraordinary additional sales rose again in connection with COVID-19, while on the other hand, drug sales for cold and flu infections rose sharply year on year.

Highlights in the 2021 financial year:

  • Extraordinary additional sales in connection with COVID-19 had a positive sales effect of 3.1%.
  • 50% growth of online sales at Amavita and Sun Store.
  • The specialty pharmacy Mediservice achieved a high increase in sales of new rare disease medications in combination with home-care services.
  • Acquisitions of companies and new products strengthened Galenica’s position in the Swiss healthcare market and opened up new market segments.
  • Further market share gains in the wholesale business with doctors have made a positive contribution to sales growth.

Improved earnings outlook

Thanks to the exceptionally strong sales growth in the last few months of 2021 and the one-off gain from the property sale of the headquarters in Bern of about CHF 9 million Galenica is increasing its earnings outlook and now expects adjusted EBIT (excluding the effects of IFRS 16 and IAS 19) to grow by between +24% and +28%. In this context, Galenica expects an extraordinary EBIT contribution related to COVID-19 between +14% and +16%.

2022 Annual General Meeting

The Board of Directors will propose Judith Meier for election as a new member at the 2022 Annual General Meeting. Judith Meier has many years of experience in the operational and strategic management of service providers in the healthcare sector. With her proven expertise and valuable experience in strategically important areas of the Group’s activities, Judith Meier is the ideal addition to the Board of Directors of the Galenica Group, particularly with regard to key topics of the strategic Care programme.

Net sales of the Galenica Group 2021

in CHF million

2021

2020

Change

Segment Products & Care 
- Retail (B2C)
  - Local Pharmacies
  - Pharmacies at Home


1,908.1
1,720.0
1,261.5
458.8

1,683.1
1,517.5
1,162.5
355.2

13.4%
13.3%
8.5%
29.2%

- Professionals (B2B)
  - Products & Brands
  - Services for Professionals


194.0
131.6
62.4

173.3
111.7
61.5

11.9%
17.8%
1.4%

Segment Logistics & IT
- Wholesale
- Logistics & IT Services


2,831.4
2,728.4
111.9

2,625.1
2,530.2
98.4

7.9%
7.8%
13.7%

Corporate and eliminations

-904.8

-828.4


Galenica Group

3,834.7

3,479.8

10.2%

Other press releases

Contact

Galenica Ltd.

Media
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58

Contact

Galenica Ltd.

Investors
Untermattweg 8
3027 Bern

Tel. +41 58 852 85 29
Fax +41 58 852 85 35